<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618575</url>
  </required_header>
  <id_info>
    <org_study_id>PBC with AIH features 1</org_study_id>
    <nct_id>NCT04618575</nct_id>
  </id_info>
  <brief_title>Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1</brief_title>
  <official_title>A Randomized Controlled Open-label Clinical Trial of Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled open-label clinical trial of ursodeoxycholic acid combined with total&#xD;
      glucosides of paeony in the treatment of PBC with AIH features 1&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">November 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical remission</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The percentage of patients in biochemical remission, defined as normalization of serum ALT and IgG levels after 24 weeks of treatment, per treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial remission</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Partial remission, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) serum levels &gt;1x Upper Limit of Normal (ULN) and &lt;2x ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal response</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Minimal response, defined as decrease of ALT or AST serum levels but still &gt;2x ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>up to 12 months</time_frame>
    <description>defined as no improvement or increase of ALT or AST serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side-effects</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Drug related side-effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Jaundice, fatigue, itching, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the proportion of blood immune cells</measure>
    <time_frame>up to 12 months</time_frame>
    <description>percentage of T cells, DC, MDSC, Treg, Breg, plasma cells, NK, NKT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">137</enrollment>
  <condition>Hepatitis</condition>
  <condition>Primary Biliary Cholangitis</condition>
  <condition>Autoimmune</condition>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid combined with total glucosides of paeony</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid combined with total glucosides of paeony</intervention_name>
    <description>Ursodeoxycholic acid combined with total glucosides of paeony</description>
    <arm_group_label>Ursodeoxycholic acid combined with total glucosides of paeony</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid only</intervention_name>
    <description>Ursodeoxycholic acid only</description>
    <arm_group_label>Ursodeoxycholic acid only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18-75 years;&#xD;
&#xD;
          2. The diagnosis of PBC is clear and does not meet the Paris criteria for diagnosing PBC&#xD;
             overlap AIH, but it needs to meet 1.0xULN &lt; ALT ≤ 3.0xULN or 1.0xULN &lt; AST ≤ 3.0xULN&#xD;
             or 1.0xULN &lt; IgG ≤ 1.3xULN, and liver pathological biopsy excludes moderate or higher&#xD;
             interface inflammation;&#xD;
&#xD;
          3. Agreed to participate in the trial, and assigned informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The presence of hepatitis A, B, C, D, or E virus infection;&#xD;
&#xD;
          2. Patients with presence of cirrhosis;&#xD;
&#xD;
          3. Patients with presence of fulminant liver failure;&#xD;
&#xD;
          4. Liver damage caused by other reasons: such as primary sclerosing cholangitis,&#xD;
             non-alcoholic steatohepatitis, drug induced liver disease or Wilson's disease;&#xD;
&#xD;
          5. Pregnant and breeding women and women of childbearing age in need of reproduction;&#xD;
&#xD;
          6. Severe disorders of other vital organs, such as severe heart failure, cancer;&#xD;
&#xD;
          7. Parenteral administration of blood or blood products within 6 months before screening;&#xD;
&#xD;
          8. Recent treatment with drugs having known liver toxicity;&#xD;
&#xD;
          9. Taken part in other clinic trials within 6 months before enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Yang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mengyi Shen, MD</last_name>
    <phone>+86 15626212342</phone>
    <email>shenmengyi1219@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Yang, MD</last_name>
    <phone>+86 13518178110</phone>
    <email>yangli_hx@scu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yang, MD</last_name>
      <phone>+8618980601276</phone>
      <email>yangli_hx@scu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 31, 2020</study_first_submitted>
  <study_first_submitted_qc>October 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Li Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

